Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and (Q81050174)
Jump to navigation
Jump to search
scientific article published on 01 September 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and |
scientific article published on 01 September 2005 |
Statements
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC (English)
I Chernozemsky
L Sirakova
P Chilingirov
R Souchon
N Marschner
U Kleeberg
C Tsekov
D Fritze
C Thomssen
N Stuart
J B Vermorken
S Loibl
Kh Merkle